biotech
biotech Articles
Recro Pharma saw its shares fall on Thursday after the company announced a secondary offering. This follows the company's recent win in its late-stage IV metoxicam trial.
Published:
Last Updated:
TiGenix has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
Clearside Biomedical has filed with the U.S. Securities and Exchange Commission regarding a secondary offering worth up to more than $86 million.
Published:
Last Updated:
Amicus Therapeutics, Inc. (NASDAQ: FOLD) is watching its shares drop on Tuesday after the company provided an update on its regulatory pathway for its Fabry Disease treatment. After the company had...
Published:
Last Updated:
Shares of Genetic Technologies practically doubled in Tuesday's session after the company announced the signing of an exclusive worldwide license agreement with the University of Melbourne.
Published:
Last Updated:
Shares of PhaseRx more than doubled on Monday after the company announced that it received a key FDA approval for its rare liver disorder treatment.
Published:
Last Updated:
The November 15 short interest data have been compared with the previous report, and short interest increased in most of the selected biotech stocks.
Published:
Last Updated:
Juno Therapeutics Inc. (NASDAQ: JUNO) saw its shares hit a new 52-week low in Wednesday’s session after the company announced a clinical hold on its JCAR015 trial. The company announced that it has...
Published:
Last Updated:
Oragenics Inc. (NYSEMKT: OGEN) saw its shares practically double late on Monday, and even continue climbing after the trading session ended, following an update from the U.S. Food and Drug...
Published:
Last Updated:
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is watching its shares slide on Monday after the company gave an update on a recent clinical study. Essentially, the company announced that its Milestone...
Published:
Last Updated:
With the market effectively at all-time highs after the election, investors are looking for new ideas to generate income or gains ahead. Sometimes investors turn to Wall Street research to look for...
Published:
Last Updated:
BeiGene intends to offer more than 4 million American depositary shares in a secondary offering valued up to more than $201 million.
Published:
Last Updated:
AnaptysBio has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
Synthetic Biologics has announced the pricing for its secondary offering and expects to make $25 million from the offering.
Published:
Last Updated:
BeyondSpring has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Last Updated: